Investors turn cold shoulder to Canadian biotechs

Anyone tracking trends in biotech financing is likely to get a chill from the latest numbers on the Canadian biotech scene. According to Desjardins Securities, a growing level of aversion to risk helped cut the flow of venture capital to a paltry $150 million in the first quarter--down from $637 million for the same period a year ago. Analyst Yagi Maher says the sudden drop has less to do with an aversion to biotechnology as an investor reluctance to go with any small cap company these days. And developers have responded by sidelining some development programs as they wait for better terms and more cash availability.

- read the story from the National Post

Suggested Articles

LianBio aims to bring much-needed new drugs to China and serve as a partner for U.S. biotechs looking to expand into Asia.

Despite the setback, Fulcrum hailed the data as “very encouraging,” zeroing in on results from a pre-specified sensitivity analysis to make its case.

Bayer has struck a $425 million upfront deal to buy KaNDy in the belief its treatment for menopause-related hot flashes has blockbuster potential.